SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai (FET) is attracting significant community attention due to its strategic focus on autonomous AI agent infrastructure and a high-profile partnership with Google Cloud. While some investors are actively accumulating the token as a long-term play on the AI narrative, others remain cautious, debating the impact of token supply dynamics and the broader volatility of the altcoin market.

Re is an internet-native marketplace for insurance capital. It connects eligible capital providers with fully collateralized reinsurance activity conducted through licensed insurance entities. Blockchain infrastructure makes collateral, reserves, and selected operating data verifiable onchain. RE is the governance token of the Re Protocol. It governs protocol upgrades, technical permissions, committee formation, reporting standards, incentive policy, and governance procedures. Underwriting, claims, pricing, reserve decisions, and regulated operations remain with qualified professionals and licensed entities.

The RE crypto token is generating significant buzz and high trading volume as investors react to its recent listings on major platforms and its institutional focus on decentralized reinsurance. Community members are actively debating its long-term potential as a real-world asset, with many closely monitoring price action and supply constraints while sharing ambitious, high-target outlooks.

Chip

Chip is currently trending as a prominent AI infrastructure play, with the community actively debating its potential as a GPU-backed lending protocol versus concerns over volatility and insider selling. Investors are closely monitoring its performance as they weigh the project's real-world use case in financing AI hardware against the risks typical of early-stage, high-beta crypto assets.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment focuses on branded generic pharmaceuticals that are manufactured worldwide and marketed and sold outside the United States, primarily in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternative care testing sites. The Nutritional Products segment oversees the worldwide sale of pediatric and adult nutritional products. The Medical Devices segment offers a broad range of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, as well as diabetes care and continuous glucose monitoring products. It also provides neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

Abbott Laboratories is experiencing significant selling pressure as investors grapple with concerns over the Exact Sciences integration, potential litigation, and broader sector rotation out of defensive healthcare stocks. While the community is debating whether the stock represents a deep-value opportunity or a long-term trap, sentiment remains divided between those expecting a structural rebound from multi-year support levels and those anticipating further downside.

ProShares Trust II - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is trending as investors react to extreme volatility in the natural gas market, fueled by persistent geopolitical tensions in the Middle East and ongoing uncertainty regarding supply routes. The community is actively debating the impact of these macro events versus technical factors like contango and leveraged decay, with many traders focusing on the short-term impact of weekly storage reports on price swings.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as traders debate its potential as an AI-native infrastructure play, with community members actively discussing its role in the agentic economy and long-term utility versus short-term price volatility. Discussions are focused on its technical integrations, such as chain abstraction and AI agent capabilities, as investors weigh these structural developments against a broader, grinding crypto market.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

Geo Group is experiencing heightened market activity as investors weigh record-breaking contract wins against ongoing concerns regarding the federal government's long-term reliance on private detention facilities. The stock remains a focal point for the community as they actively debate the potential for future asset sales, the impact of shifting DHS immigration policies, and the implications of founder George Zoley's return to the CEO role.

Spire Global, Inc. collects space-based data using a proprietary constellation of low earth multi-use receiver nanosatellites. Its software analytics generate proprietary data, insights and predictive analytics for its customers through a subscription model. The company was founded by Peter Platzer in August 2012 and is headquartered in Vienna, VA.

Spire Global Inc - Ordinary Shares - Class A

Spire Global is generating significant community buzz following its inclusion in a massive multi-billion dollar missile defense contract, sparking optimism about its long-term potential in sovereign space defense. Investors are actively discussing the stock's transition toward high-margin data analytics and a path to profitability, though sentiment remains tempered by ongoing debates regarding the company's management and past volatility.

Select Sector SPDR Trust (The) - State Street Health Care Select Sector SPDR ETF

Health Care Select Sector SPDR Fund

The Health Care Select Sector SPDR Fund (XLV) is currently in focus as investors lean into defensive rotation, with the sector showing technical strength and a series of constructive setups amid broader market volatility. Community discussions are heavily centered on the ETF's role as a hedge against potential tech sector weakness, with many traders monitoring its technical breakout levels and sector rotation flows to identify buy opportunities.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

MRK is trending as investors react to its latest quarterly results, where strong growth in Keytruda sales helped offset declines in Gardasil, while the market also processes the implications of the company's recent strategic acquisitions. The community is actively debating the stock's long-term growth potential and pipeline execution as it navigates a challenging regulatory environment and prepares for upcoming patent expirations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LH or CRL: Which Is the Better Value Stock Right Now?

LH vs. CRL: Which Stock Is the Better Value Option?

Labcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026

Labcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026 Labcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026 PR Newswire BURLINGTON, N.C., June 30, 2026 BURLINGTON, N.C., June 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of...

Omada Health, Inc. (OMDA) Stock Jumps 10.5%: Will It Continue to Soar?

Omada Health, Inc. (OMDA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Is it the Right Time to Add Labcorp Stock to Your Portfolio?

LH expands specialty testing, acquisitions and AI initiatives to drive growth, but macro pressures and currency headwinds could weigh on results. 

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Natera (NTRA) Stock Jumps 10.7%: Will It Continue to Soar?

Natera (NTRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

How Are Emerging Markets Supporting Abbott's EPD Momentum?

ABT's Emerging Markets drive EPD growth, with strong branded generics demand, biosimilar expansion and new approvals boosting momentum. 

How to Approach Abbott Stock Following Its Sharp YTD Decline?

ABT falls 29.4% YTD as respiratory testing weakness, China uncertainty and acquisition dilution pressure results and outlook.

Labcorp Announces Nationwide Availability of ColoSense, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test

Labcorp Announces Nationwide Availability of ColoSense, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test Labcorp Announces Nationwide Availability of ColoSense, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test PR Newswire BURLINGTON, N.C. and ST...

Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates through the Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS) segments. The Dx segment includes routine and specialty esoteric testing. The BLS segment consists of central laboratory and ED businesses. The company was founded in 1995 and is headquartered in Burlington, NC.

Labcorp Holdings Inc.

Labcorp Raises Full Year Guidance After Q2 Earnings Beat Wall Street Expectations: Retail Sees Rally To $330

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$4.79	--	--	N/A
Q1 '26	$4.11	$4.25	3.42%	BEAT
Q4 '25	$3.94	$4.07	3.17%	BEAT
Q3 '25	$4.13	$4.18	1.12%	BEAT
Q2 '25	$4.17	$4.35	4.37%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

LHLaboratory Corp. Of America Holdings

Upcoming Earnings: Q2 '26

Historical Earnings

Latest LH News